Company profile

MAXCYTE, INC.

NASDAQ:MXCTBiotechnology: Commercial Physical & Biological Resarch

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03608618phase1terminated2018-08-272021-02-11MaxCyte, Inc.Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

FDA applications (0)

No records yet.